Table 4.
The estimated parameters used to predict the pharmacodynamics of leuprolide using the developed PK–PD model (mean ± SE, n = 5).
| Parameters | Wistar Rats | Iar:COP Rats | ||
|---|---|---|---|---|
| Solution-IV (Group 1) | Solution-SC (Group 3) | SR-SC (Group 4) | SR-SC (Group 6) | |
| kin(h−1) | 0.68 | 0.68 | 0.68 | 0.35 |
| kout (h−1) | 0.16 | 0.16 | 0.16 | 0.06 |
| h | 2.00 ± 0.61 | 2.02 ± 0.05 | 2.00 ± 0.01 | 3.18 ± 1.27 |
| Emax | 303.77 ± 12.90 | 183.50 ± 12.87 | 380.00 ± 87.54 | 634.50 ± 144.73 * |
| EC50 (ng/mL) | 3.48 ± 1.74 | 6.17 ± 2.49 | 1.80 ± 0.57 | 3.34 ± 0.56 * |
| kf,on (h−1) | 0.29 ± 0.19 | 0.14 ± 0.03 | 0.40 ± 0.25 | 0.083 ± 0.14 |
| kf,off (h−1) | 0.059 ± 0.017 | 0.02 ± 0.014 | 0.04 ± 0.032 | 0.45 ± 0.04 |
* p < 0.05 between Wistar and Iar:COP rats administered SR–SC.